Cargando…
Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood
A specific humoral response to bacteriophages may follow phage application for medical purposes, and it may further determine the success or failure of the approach itself. We present a long-term study of antibody induction in mice by T4 phage applied per os: 100 days of phage treatment followed by...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576206/ https://www.ncbi.nlm.nih.gov/pubmed/26308042 http://dx.doi.org/10.3390/v7082845 |
_version_ | 1782390858781294592 |
---|---|
author | Majewska, Joanna Beta, Weronika Lecion, Dorota Hodyra-Stefaniak, Katarzyna Kłopot, Anna Kaźmierczak, Zuzanna Miernikiewicz, Paulina Piotrowicz, Agnieszka Ciekot, Jarosław Owczarek, Barbara Kopciuch, Agnieszka Wojtyna, Karolina Harhala, Marek Mąkosa, Mateusz Dąbrowska, Krystyna |
author_facet | Majewska, Joanna Beta, Weronika Lecion, Dorota Hodyra-Stefaniak, Katarzyna Kłopot, Anna Kaźmierczak, Zuzanna Miernikiewicz, Paulina Piotrowicz, Agnieszka Ciekot, Jarosław Owczarek, Barbara Kopciuch, Agnieszka Wojtyna, Karolina Harhala, Marek Mąkosa, Mateusz Dąbrowska, Krystyna |
author_sort | Majewska, Joanna |
collection | PubMed |
description | A specific humoral response to bacteriophages may follow phage application for medical purposes, and it may further determine the success or failure of the approach itself. We present a long-term study of antibody induction in mice by T4 phage applied per os: 100 days of phage treatment followed by 112 days without the phage, and subsequent second application of phage up to day 240. Serum and gut antibodies (IgM, IgG, secretory IgA) were analyzed in relation to microbiological status of the animals. T4 phage applied orally induced anti-phage antibodies when the exposure was long enough (IgG day 36, IgA day 79); the effect was related to high dosage. Termination of phage treatment resulted in a decrease of IgA again to insignificant levels. Second administration of phage induces secretory IgA sooner than that induced by the first administrations. Increased IgA level antagonized gut transit of active phage. Phage resistant E. coli dominated gut flora very late, on day 92. Thus, the immunological response emerges as a major factor determining phage survival in the gut. Phage proteins Hoc and gp12 were identified as highly immunogenic. A low response to exemplary foreign antigens (from Ebola virus) presented on Hoc was observed, which suggests that phage platforms can be used in oral vaccine design. |
format | Online Article Text |
id | pubmed-4576206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-45762062015-09-28 Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood Majewska, Joanna Beta, Weronika Lecion, Dorota Hodyra-Stefaniak, Katarzyna Kłopot, Anna Kaźmierczak, Zuzanna Miernikiewicz, Paulina Piotrowicz, Agnieszka Ciekot, Jarosław Owczarek, Barbara Kopciuch, Agnieszka Wojtyna, Karolina Harhala, Marek Mąkosa, Mateusz Dąbrowska, Krystyna Viruses Article A specific humoral response to bacteriophages may follow phage application for medical purposes, and it may further determine the success or failure of the approach itself. We present a long-term study of antibody induction in mice by T4 phage applied per os: 100 days of phage treatment followed by 112 days without the phage, and subsequent second application of phage up to day 240. Serum and gut antibodies (IgM, IgG, secretory IgA) were analyzed in relation to microbiological status of the animals. T4 phage applied orally induced anti-phage antibodies when the exposure was long enough (IgG day 36, IgA day 79); the effect was related to high dosage. Termination of phage treatment resulted in a decrease of IgA again to insignificant levels. Second administration of phage induces secretory IgA sooner than that induced by the first administrations. Increased IgA level antagonized gut transit of active phage. Phage resistant E. coli dominated gut flora very late, on day 92. Thus, the immunological response emerges as a major factor determining phage survival in the gut. Phage proteins Hoc and gp12 were identified as highly immunogenic. A low response to exemplary foreign antigens (from Ebola virus) presented on Hoc was observed, which suggests that phage platforms can be used in oral vaccine design. MDPI 2015-08-20 /pmc/articles/PMC4576206/ /pubmed/26308042 http://dx.doi.org/10.3390/v7082845 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Majewska, Joanna Beta, Weronika Lecion, Dorota Hodyra-Stefaniak, Katarzyna Kłopot, Anna Kaźmierczak, Zuzanna Miernikiewicz, Paulina Piotrowicz, Agnieszka Ciekot, Jarosław Owczarek, Barbara Kopciuch, Agnieszka Wojtyna, Karolina Harhala, Marek Mąkosa, Mateusz Dąbrowska, Krystyna Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood |
title | Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood |
title_full | Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood |
title_fullStr | Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood |
title_full_unstemmed | Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood |
title_short | Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood |
title_sort | oral application of t4 phage induces weak antibody production in the gut and in the blood |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576206/ https://www.ncbi.nlm.nih.gov/pubmed/26308042 http://dx.doi.org/10.3390/v7082845 |
work_keys_str_mv | AT majewskajoanna oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT betaweronika oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT leciondorota oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT hodyrastefaniakkatarzyna oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT kłopotanna oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT kazmierczakzuzanna oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT miernikiewiczpaulina oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT piotrowiczagnieszka oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT ciekotjarosław oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT owczarekbarbara oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT kopciuchagnieszka oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT wojtynakarolina oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT harhalamarek oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT makosamateusz oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood AT dabrowskakrystyna oralapplicationoft4phageinducesweakantibodyproductioninthegutandintheblood |